New drug application 21-628, Certican (everolimus), for the proposed indication of prophylaxis of rejection in heart transplantation: report from the Cardiovascular and Renal Drugs Advisory Committee, US Food and Drug Administration, November 16, 2005, Rockville, Md.
Hiatt
William R
WR
Department of Medicine, University of Colorado Health Sciences Center, Denver, CO 80203, USA. will.hiatt@uchsc.edu
Nissen
Steven E
SE
D017277:Drug Approval; D000068338:Everolimus; D006084:Graft Rejection / Q000517:prevention & control*; D016027:Heart Transplantation / Q000379:methods*; D006801:Humans; D017387:Investigational New Drug Application; D016030:Kidney Transplantation / Q000379:methods; D011292:Premedication; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000068338:Everolimus; D020123:Sirolimus